CEL-SCI

CEL-SCI ROIC

The Return on Invested Capital (ROIC) of CEL-SCI (CVM) as of Nov 2, 2026 is -100.28 %. In the previous year, Return on Invested Capital (ROIC) was -109.93 % — a change of -8.78% (higher).

ROIC

-100.28 %

YoY

-8.78%

Last updated:

Return on Invested Capital (ROIC) of CEL-SCI is 2025 -100.28 % . Return on Invested Capital (ROIC) of CEL-SCI was 2024 -109.93 % . It decreases by -8.78% higher compared to the previous year.

The CEL-SCI ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-223.82 USD
Jan 1, 2019
-131.58 USD
Jan 1, 2020
-89.94 USD
Jan 1, 2021
-50.15 USD
Jan 1, 2022
-77.32 USD
Jan 1, 2023
-120.83 USD
Jan 1, 2024
-109.93 USD
Jan 1, 2025
-100.28 USD
The CEL-SCI ROIC history
YEARROICYoY
-100.28 %-8.78%
-109.93 %-9.02%
-120.83 %+56.27%
-77.32 %+54.18%
-50.15 %-44.24%
-89.94 %-31.65%
-131.58 %-41.21%
-223.82 %+69.37%
-132.15 %+41.89%
-93.13 %-76.33%
-393.53 %+66.31%
-236.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CEL-SCI Stock analysis

What does CEL-SCI do? CEL-SCI Corp develops immunotherapies targeting cancer and infectious diseases, focusing on Multikine for head and neck cancers and anal warts in HIV/HPV co-infected patients, and L.E.A.P.S. technology for influenza and rheumatoid arthritis treatments. The company generates revenue through research and development services, with products like LEAPS-H1N1-DC and CEL-2000/CEL-4000 in clinical development. Its primary customers are pharmaceutical partners and research institutions seeking novel therapeutic solutions. The firm operates within the biotechnology sector, emphasizing immune system activation for disease treatment. Multikine and L.E.A.P.S. therapies represent CEL-SCI's core product pipeline, with Multikine targeting head and neck cancers and cervical dysplasia, while L.E.A.P.S. focuses on pandemic influenza and rheumatoid arthritis. The company monetizes its R&D efforts by advancing these therapies through clinical trials, aiming for partnerships with larger pharmaceutical firms for commercialization. Its segment is defined by the development of investigational drugs and vaccines, with no current commercial products generating direct revenue. CEL-SCI's revenue model relies on securing funding for clinical trials and potential future licensing agreements. The company's focus on immune-based therapies for unmet medical needs attracts interest from biotech investors and collaborative partners. Its product candidates, including LEAPS-H1N1-DC and CEL-2000, are positioned for development into marketable treatments, though no sales have occurred yet. CEL-SCI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CEL-SCI stock

Return on Invested Capital (ROIC) of CEL-SCI is -100.28 % in 2025.

Return on Invested Capital (ROIC) of CEL-SCI changed from -109.93 % to -100.28 %, representing a -8.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) CEL-SCI since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s CEL-SCI with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — CEL-SCI

All Key Metrics — CEL-SCI